Kras g12c inhibitors and methods of using the same
US-2019375749-A1 · Dec 12, 2019 · US
Synthesis of key intermediate of KRAS G12C inhibitor compound
US12391689B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12391689-B2 |
| Application number | US-202217689741-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 8, 2022 |
| Priority date | Nov 16, 2018 |
| Publication date | Aug 19, 2025 |
| Grant date | Aug 19, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as
First claim
Opening claim text (preview).
What is claimed is: 1. A composition, the composition comprising a compound of Formula 4: and a compound of Formula B: 2. The composition of claim 1 , wherein the compound of Formula 4 is: 3. The composition of claim 1 , wherein the compound of Formula 4 is: 4. The composition of claim 1 , wherein the compound of Formula B is: 5. The composition of claim 1 , wherein the compound of Formula B is: 6. The composition of claim 1 , wherein the composition comprises a 2 to 1 ratio of the compound of Formula 4 to the compound of Formula B. 7. The composition of claim 1 , wherein the composition further comprises 2-methyltetrahydrofuran having the formula: 8. The composition of claim 7 , wherein the ratio of the 2-methyltetrahydrofuran to the compound of formula B is 2 to 1. 9. The composition of claim 7 , wherein the composition comprises: 10. The composition of claim 9 , wherein the composition comprises: 11. The composition of claim 9 , wherein the composition comprises: 12. The composition of claim 9 , wherein the composition comprises: 13. The composition of claim 9 , wherein the composition comprises:
Assignees
Inventors
Classifications
Separation of optically-active compounds · CPC title
- C07C309/24Primary
of a carbon skeleton containing six-membered aromatic rings · CPC title
Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring · CPC title
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12391689B2 cover?
- The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C309/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).